LA-DRB (Major Histocompatibility Complex, Class II, DR Beta) plays an important role in antigen presentation and has been shown to represent a predictive biomarker for response to anti-PD1 therapy and the overall survival of patients with melanoma [51,52]. The gene discussed is PDCD1; the disease is melanoma.